News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rhode Island Biotech EpiVax, Inc. Receives $500K Federal Grant to Reengineer FVIII using ''Immunoinformatics''



6/27/2007 12:52:20 PM

PROVIDENCE, R.I.--(BUSINESS WIRE)--EpiVax, Inc, a leader the field of second generation protein therapeutics, announced today that it has received a grant to reengineer Factor VIII (FVIII), the primary therapeutic used to control bleeding for individuals who have acquired or hereditary hemophilia.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES